Ipsen opened its new manufacturing site in Blanchardstown in Dublin, Ireland last week following a €52 million investment.
Irish news outlet RTE reported the opening on Sept. 26. The report said the investment aims to upgrade and expand the existing facility’s capabilities.
The improved site features 175 employees, according to RTE. Ipsen’s Ireland R&D and manufacturing teams have scaled active pharmaceutical ingredient production by 10% year-over-year as a result of the facility’s improvements, the report said. Ipsen stated that the investment supported the “extension and acceleration of vital medicine production.”
Expansion in Ireland represents Ipsen’s recognition of the Irish market’s important role in its international network, the report said. Ipsen intends to continue growth as a provider of care across oncology, rare diseases and neuroscience.
“Ipsen is committed to continued investment a…